Evidence map›Paper›PMID 38317265›Full record

ArticleTranslational neurodegeneration2024

Life and disease status of patients with Parkinson's disease during and after zero-COVID in China: an online survey.

Pei Huang, Yu-Yan Tan, Biao Chen, Hui-Fang Shang, Li-Juan Wang, Chun-Feng Liu, Ling Chen, Ying Chang, Han Wang, Xue-Lian Wang and 6 more

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational neurodegeneration, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 14 institutions in 1 country.

Pei Huang *Department of Neurology and Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Yu-Yan Tan *Department of Neurology and Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Biao ChenDepartment of Neurology, Xuan Wu Hospital Affiliated to Capital Medical University, Beijing, 100053, China.
Hui-Fang ShangDepartment of Neurology, West China Hospital, Sichuan University, Chengdu, 610041, China.
Li-Juan WangDepartment of Neurology, Guangdong General Hospital, Guangzhou, 510080, China.
Chun-Feng LiuDepartment of Neurology, Suzhou Clinical Research Center of Neurological Disease, The Second Affiliated Hospital of Soochow University, Suzhou, 215004, China.
Ling ChenDepartment of Neurology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510080, China.
Ying ChangDepartment of Neurology, China-Japan Union Hospital, Jilin University, Changchun, 130031, China.
Han WangDepartment of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
Xue-Lian WangDepartment of Neurosurgery, West China Hospital, Sichuan University, Chengdu, 610041, China.
Xiao-Guang LeiDepartment of Neurology, The First Affiliated Hospital of Kunming Medical University, Kunming, 650032, China.
Li-Fen YaoDepartment of Neurology, The First Affiliated Hospital of Harbin Medical University, Harbin, 150001, China.
Yang YuDepartment of Neurology, Tianjin Huanhu Hospital, Tianjin, 300350, China.
Zheng YeInstitute of Neuroscience, Center for Excellence in Brain Science and Intelligence Technology, Chinese Academy of Sciences, Shanghai, 200031, China.
Hai-Bo ChenDepartment of Neurology, Beijing Hospital, National Center of Gerontology, Beijing, 100730, China. chenhbneuro@263.net.
Sheng-Di ChenDepartment of Neurology and Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. chensd@rjh.com.cn.ORCID 0000-0002-6242-1025
Shanghai Jiao Tong University · CNSichuan University · CNBeijing Hospital · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNChinese Academy of Sciences · CNGuangdong General Hospital · CNHarbin Medical University · CNKunming Medical University · CNShanghai University · CNSoochow University · CNSun Yat-sen University · CNTianjin Huanhu Hospital · CNUnion Hospital · CNXuan Wu Hospital of the Capital Medical University · CN

Funding

National Natural Science Foundation of China 81971183National Natural Science Foundation of China 81971187National Natural Science Foundation of China 82171401National Natural Science Foundation of China 82371414Science and Technology Commission of Shanghai Municipality 2018SHZDZX05
6 · The paper itself

Abstract

backgroundLittle is known about the impact of the COVID-19 pandemic on patients with Parkinson's disease (PD) at different stages of the pandemic. This study aims to assess the lives and disease status of PD patients during the zero-COVID policy period and after ending the zero-COVID policy.

methodsThis multicenter cross-sectional study included two online surveys among PD patients in China, from May 30 to June 30 in 2022 and from January 1 to February 28 in 2023, respectively. The survey questionnaires contained four sections: (1) status of COVID-19 infection; (2) impact on motor and non-motor symptoms; (3) impact on daily and social lives; and (4) impact on PD disease management.

resultsA total of 1764 PD patients participated in the first online survey, with 200 patients having lockdown experience and 3 being COVID-19-positive (0.17%). In addition, 537 patients participated in the second online survey, with 467 patients having COVID-19 infection (86.96%). (1) During zero-COVID, all of the COVID-19-positive patients had mild symptoms of COVID-19 and no death was reported. After zero-COVID, 83.51% of the COVID-19-positive patients had mild symptoms. The overall death rate and inpatient mortality rate of COVID-19-positive PD patients were 3.21% and 30.00%, respectively. (2) During zero-COVID, 49.43% of PD patients reported worsening of PD-related symptoms (lockdown vs. unlockdown, 60.50% vs. 48.02%, P = 0.0009). After zero-COVID, 54.93% of PD patients reported worsening of PD-related symptoms (COVID-19 positive vs. COVID-19 negative, 59.31% vs. 25.71%, P < 0.0001). (3) During zero-COVID, 62.36% of patients felt worried, and 'limited outdoor activities' (55.39%) was the top reason for mental health problems. After zero-COVID, 59.03% of patients felt worried, with 'poor health' (58.10%) being the top reason. The PD patients tended to change their daily activities from offline to online, and their economic and caregiver burdens increased both during and after zero-COVID. (4) Most PD patients would like to choose online rehabilitation during (69.56%) and after zero-COVID (69.27%). The demand for online medication purchasing also increased during (47.00%) and after zero-COVID (26.63%).

conclusionsThe COVID-19 pandemic aggravated the motor and non-motor symptoms of PD patients either during or after the zero-COVID policy period. The PD patients also experienced prominent mental health problems, changes in daily activities, and increases in economic and caregiver burdens. The COVID-19 pandemic has changed ways of PD management with increasing demands for online medication purchasing and rehabilitation.

Indexed as

COVID-19Parkinson DiseaseChinaCommunicable Disease ControlCross-Sectional StudiesHumansPandemicsSurveys and QuestionnairesCOVID-19InfectionLockdownParkinson’s diseaseZero-COVID

Identifiers

PMID38317265
PMCPMC10845503
OpenAlexW4391573064

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.